Partnership is helping to provide access to hemophilia treatment worldwide

There are an estimated 400,000 people living with hemophilia worldwide, and around 75% have limited or no access to treatment, particularly in the developing world. Many people with severe hemophilia in these countries don’t survive to adulthood due to a lack of treatment. Sobi and Sanofi Genzyme continue to support the 2014 pledge to donate up to 1 billion IUs of factor therapy over ten years to the developing world, including 500 million IUs to the World Federation of Hemophilia. Already, nearly 17,000 people with hemophilia have been treated.